Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06235697 · ClinicalTrials.gov registry record · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
A Phase 3 study of Prostate Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
- 20
- Study locations
NCT06235697 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 710 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 1 state.
The verdict
NCT06235697, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Conditions Studied
Interventions
- RADIATION Radiation
- RADIATION Radiation SBRT only
- DRUG ADT
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente- Marshall Medical Offices - Redwood City
- Kaiser Permanente-Richmond - Richmond
- Kaiser Permanente-Roseville - Roseville
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- Kaiser Permanente Downtown Commons - Sacramento
- Kaiser Permanente-South Sacramento - Sacramento
- Kaiser Permanente-San Francisco - San Francisco
- Kaiser Permanente-Santa Teresa-San Jose - San Jose
- Kaiser Permanente San Leandro - San Leandro
- Kaiser San Rafael-Gallinas - San Rafael
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- Kaiser Permanente-Santa Rosa - Santa Rosa
- Kaiser Permanente-South San Francisco - South San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2024-04-25 |
| Est. Completion | 2033-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06235697
The ClinicalTrials.gov registry entry for NCT06235697 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (17% higher). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Radiation is the first listed.
NCT06235697 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06235697 about?
NCT06235697 is a clinical study titled "Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment". This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation th...
What is the current status of trial NCT06235697?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2024-04-25. Estimated completion is 2033-04-30.
What conditions does trial NCT06235697 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06235697?
The interventions under investigation include: Radiation (RADIATION), Radiation SBRT only (RADIATION), ADT (DRUG).
Who is sponsoring clinical trial NCT06235697?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06235697 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.